Option chain shows key data for Grace Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Grace Therapeutics.

Grace Therapeutics (NASDAQ:GRCE) Stock, Option Chain

Grace Therapeutics

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

GRCE

Biotech

News

Health Care

Financing

Offerings

Movers

Trading Ideas

General

Grace Therapeutics&#39; GTx-104 met its Phase 3 trial endpoint, showing clinical benefits over oral nimodipine. US NDA submission is expected in early 2025.

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

Grace Therapeutics Inc

Keybanc analyst John Vinh maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Overweight and raises the price target from $70 to $75.

Price Target

Analyst Ratings

LSCC

Keybanc Maintains Overweight on Lattice Semiconductor, Raises Price Target to $75

Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) announced that it will integrate its Inspection and Reconditioning Center capabilities into the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43618819/carvana-announces-auction-irc-megasite-integration-in-indianapolis" rel="noreferrer noopener">existing ADESA Indianapolis wholesale auction site.</a>
The new &#8220;Megasite&#8221; will combine Carvana&#8217;s digital and in-lane auction operations with reconditioning services, boosting the company&#8217;s production capacity and offering serviceS to retail and wholesale customers in the Indianapolis area.
The transition is expected to create approximately 200 new jobs locally.
The ADESA Indianapolis site in Plainfield spans over 100 acres and includes nearly 12,000 parking spaces, providing infrastructure for Carvana&#8217;s expanded operations.
The site has been a significant player in the wholesale automotive market, and Carvana&#8217;s integration of IRC capabilities will add another layer to its offerings.
Also Read:<a target="_blank" href="https://www.benzinga.com/25/02/43618537/bp-q3-results-lower-revenue-rising-debt-but-175-billion-buyback-and-dividend-hike-impress" rel="noreferrer noopener"> BP Q4 Results: Lower Revenue, Rising Debt, CEO Pledges Fundamental Strategy Shift And More</a>
Carvana&#8217;s move to expand its reconditioning capacity through this integration enhances its nationwide inventory, offering local customers quicker access to vehicles with potential same-day delivery.
Additionally, wholesale customers will benefit from enhanced auction operations, supported by Carvana&#8217;s CARLI software.
Mike Caggiano, Executive Vice President of Operations at ADESA, emphasized the integration&#8217;s potential to improve services for retail and wholesale customers while also creating new job opportunities. This development represents a significant step in Carvana&#8217;s efforts to strengthen its operational footprint and improve delivery efficiency in the region.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, CVNA stock has gained over 387% in the past year. Investors can gain exposure to the stock via&nbsp;Invesco Dorsey Wright Consumer Cyclicals Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEZ#NASDAQ">PEZ</a>).
Price Action: CVNA shares are trading higher by 0.55% to $269.29 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43614105/activist-investor-elliott-builds-25-billion-stake-in-phillips-66-pressures-for-midstream-spinoff-report" target="_blank" rel="noreferrer noopener">Activist Investor Elliott Builds $2.5 Billion Stake In Phillips 66, Pressures For Midstream Spinoff: Report</a></li>
</ul>
Photo via Shutterstock.

Equities

Markets

CVNA

PowerShares Dynamicnsumer Discretionary Sector Portfolio

What's Going On With Carvana Stock Today?

WIIM

RGNX

Regenxbio shares are trading lower after Goldman Sachs downgraded the stock from Buy to Neutral and cut its price target from $38 to $14.

Kinross Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) has outperformed the market over the past 5 years by 5.19% on an annualized basis producing an average annual return of 17.57%. Currently, Kinross Gold has a market capitalization of $14.69 billion. 
Buying $1000 In KGC: If an investor had bought $1000 of KGC stock 5 years ago, it would be worth $2,366.34 today based on a price of $11.95 for KGC at the time of writing.
<h3>Kinross Gold's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739286930_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Kinross Gold 5 Years Ago Would Be Worth Today

Few speeches stand the test of time, but Steve Jobs' <a href="https://youtu.be/UF8uR6Z6KLc?si=5m6XEuBXuhMilRXI">2005 Stanford University commencement address </a>isn't just remembered—it's studied, quoted, and dissected like scripture for the modern entrepreneur. It wasn't a formulaic "go chase your dreams" pep talk. Instead, Jobs used his own life—dropping out of college, getting fired from Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), facing death—to remind graduates that life is unpredictable, and the only real mistake is not following your own path.
<h2 class="wp-block-heading">The Speech That Defined a Generation</h2>
When <a href="https://www.benzinga.com/tech/25/02/43578844/bill-gates-says-steve-jobs-once-told-him-i-wish-youd-take-acid-that-would-enhance-microsofts-product-design-more-i-envy-those-skills-im-not-in-his-league">Steve Jobs took the stage</a> at Stanford, he wasn't a struggling entrepreneur. He was Steve Freaking Jobs—the visionary behind Apple, Pixar, and the Macintosh, standing at the peak of his career. Yet, instead of a victory lap, he delivered a brutally honest message:
"Your time is limited, so don't waste it living someone else's life."
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
He wasn't talking about reckless ambition or quitting your job tomorrow. He was talking about trusting yourself—even when life doesn't go according to plan.
<h2 class="wp-block-heading">Lesson #1: "You Can't Connect the Dots Looking Forward"</h2>
Jobs dropped out of Reed College after six months. No plan, no roadmap—just instinct. He floated from class to class, crashing on friends' dorm floors, collecting Coke bottle deposits for food, and walking seven miles for a good meal at a Hare Krishna temple.
One class he "randomly" took? Calligraphy.
It seemed useless at the time. But 10 years later, that knowledge helped Jobs design the first Macintosh, making it the first personal computer with beautiful typography. If he hadn't dropped out, computers might still look like government spreadsheets.
"You have to trust that the dots will somehow connect in your future," he said.&nbsp;
The takeaway? You don't always see where you're headed—but looking back, every choice matters.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
<h2 class="wp-block-heading">Lesson #2: "Sometimes Life Hits You in the Head with a Brick. Don't Lose Faith."</h2>
At 30, Jobs was at the top of the world—running Apple, the company he co-founded. Then, Apple fired him. His own board, the one he built, kicked him out of his own company.
Public humiliation. Industry outcast. Game over, right? Not for Jobs.
"Getting fired from Apple was the best thing that could have ever happened to me," he said.&nbsp;
Without Apple, he was free. He launched NeXT and Pixar, two companies that would define modern animation and <a href="https://www.benzinga.com/startups/25/01/42858542/steve-jobs-said-hiring-seasoned-professionals-at-apple-didnt-work-because-most-of-them-were-bozos-who-didnt-know-how-to-do-anything">Apple's comeback</a>. When Apple eventually bought NeXT, he returned as CEO—this time, to build the iPhone.
The lesson? Failure isn't the end. It's a reset.
Trending: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<h2 class="wp-block-heading">Lesson #3: "Death is Life's Change Agent."</h2>
Then, Jobs dropped a reality check: one day, you will die.
A year before the speech, Jobs was diagnosed with pancreatic cancer and given three to six months to live. He spent the day preparing for the end—only to find out his cancer was rare and curable.
But the wake-up call stuck with him.
"Remembering that you are going to die is the best way I know to avoid the trap of thinking you have something to lose," he said.&nbsp;
When death is inevitable, why live by someone else's expectations? Why play it safe?
See Also: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
<h2 class="wp-block-heading">Final Words: "Stay Hungry. Stay Foolish."</h2>
Jobs ended with a quote from The Whole Earth Catalog, a 1970s book that inspired him. The words?
"Stay hungry. Stay foolish."
In other words: Don't settle. Keep pushing. Be curious. Take risks.
That was Jobs' real message. Not just for Stanford graduates, but for anyone afraid of making the wrong move. Because in the end, the only real failure is not trusting yourself enough to try.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>

Personal Finance

AAPL

Steve Jobs Delivered Powerful Life Message In His Most Memorable Speech: 'Your Time is Limited So Don't Waste It Living Someone Else's Life'

In the current session, the stock is trading at $69.86, after a 1.19% increase. Over the past month, Western Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) stock increased by 11.44%, and in the past year, by 24.68%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1739286908_0.png" alt="Past Year Chart" />

<h3>Comparing Western Digital P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Western Digital has a lower P/E than the aggregate P/E of 33.87 of the Technology Hardware, Storage &amp; Peripherals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1739286908_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: Western Digital

Canaccord Genuity analyst Austin Moeller maintains Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) with a Buy and raises the price target from $18 to $24.

SPIR

Canaccord Genuity Maintains Buy on Spire Global, Raises Price Target to $24

AIOT

PowerFleet shares are trading higher after Northland Capital Markets raised its price target on the stock from $10 to $11.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Richard Law initiated coverage on Silence Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) with a Sell rating and announced a price target of $6. Silence Therapeutics shares closed at $4.92 on Monday. <a href="https://www.benzinga.com/quote/SLN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth MKM analyst George Kelly initiated coverage on Gaia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) with a Buy rating and announced a price target of $10. Gaia shares closed at $5.00 on Monday. <a href="https://www.benzinga.com/quote/GAIA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Gerry Sweeney initiated coverage on AZZ Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) with a Buy rating and announced a price target of $108. AZZ shares closed at $97.55 on Monday. <a href="https://www.benzinga.com/quote/AZZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Glen Santangelo initiated coverage on Waystar Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAY#NASDAQ">WAY</a>) with a Buy rating and announced a price target of $51. Waystar shares closed at $41.45 on Monday. <a href="https://www.benzinga.com/quote/WAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer analyst Param Singh initiated coverage on International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with an Outperform rating and announced a price target of $320. IBM shares closed at $249.27 on Monday. <a href="https://www.benzinga.com/quote/IBM/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AZZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="625" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11075847/image-2-25-1024x625.png" alt="" class="wp-image-776492" style="width:601px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11075847/image-2-25-1024x625.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11075847/image-2-25-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11075847/image-2-25-768x469.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11075847/image-2-25.png 1091w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43592071/top-3-tech-stocks-that-may-jump-this-month">Top 3 Tech Stocks That May Jump This Month</a></li>
</ul>

Initiation

Pre-Market Outlook

GAIA

STLD

This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Keybanc analyst Eric Heath maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Overweight and raises the price target from $395 to $480.

CRWD

Keybanc Maintains Overweight on CrowdStrike Holdings, Raises Price Target to $480

Canaccord Genuity analyst David Hynes maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Buy and raises the price target from $310 to $375.

MNDY

Canaccord Genuity Maintains Buy on Monday.Com, Raises Price Target to $375

On Tuesday, Cannabis producer&nbsp;Organigram Holdings Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>)&nbsp;reported first-quarter 2025 gross sales of CA$66.8 million, up 19% year-over-year, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of CA$65.4 million</a>.
21% of harvests came from higher efficiency seed-based cultivation, up from 9% in the prior quarter.
Net revenues increased 17% to CA$42.73 million, primarily due to increased recreational cannabis sales, international sales and <a href="https://www.benzinga.com/pressreleases/25/02/b43617390/organigram-reports-first-quarter-fiscal-2025-results" target="_blank" rel="noreferrer noopener">contributions from Motif sales</a>.
The company adds that the integration of Motif is progressing as planned, with over CA$10 million in annual run-rate synergies expected to be realized within the next two years.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/42882766/dea-accused-of-bias-in-cannabis-rescheduling-hearings-weed-stocks-plummeted-in-2024-as-process-drags-on" rel="noreferrer noopener">DEA Accused Of Bias In Cannabis Rescheduling Hearings: Weed Stocks Plummeted In 2024 As Process Drags On</a>
Adjusted gross margin&nbsp;was CA$14.3 million, or 33% of net revenue, compared to CA$11.2 million, or 31%, a year ago. The increase is attributable to several factors, including lower cultivation and post-harvest costs, reduced inventory provisions, and sales mix.
Adjusted EBITDA was $1.4 million compared to $0.1 million in adjusted EBITDA in Q1 Fiscal 2024. The increase was primarily attributable to higher revenue and operational efficiency gains.
&#8220;This is an exciting time for Organigram as we kick off Fiscal 2025 as Canada&#8217;s largest recreational cannabis company by market share,&#8221; said CEO Beena Goldenberg. &#8220;Our strategic priorities for the fiscal year focus on integrating Motif to maximize operational synergies, continuing to expand our presence in international markets, and driving even more innovation—both in our product portfolio to delight our consumers, and also within our operations to enhance value for our shareholders.&#8221;
The cannabis company reported a net loss of CA$22.9 million compared to a net loss of CA$15.8 million a year ago, primarily attributable to a higher fair value loss recognized in relation to top-up-rights of BAT, which was partially offset by an increase in gross margin and fair value gain on other financial assets.
As of December 31, 2024, the company had cash of CA$71.2 million. On a pro forma basis, Organigram will have a cash position of approximately CA$113 million&nbsp;upon closing the final tranche of BAT&#8217;s follow-on investment.
Price Action: OGI stock is down 11% at $1.54 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/02/43601884/momentus-wins-defense-department-contract-expansion-stock-skyrockets" target="_blank" rel="noreferrer noopener">Momentus Wins Defense Department Contract Expansion, Stock Skyrockets</a></li>
</ul>
Photo: Shutterstock

Cannabis

Earnings

Cannabis Producer Organigram Q1 Sales Jump 17%, Expect C$10 Million From Motif Integration, Annual Run-Rate Synergies Within Two Years

U.S. stocks traded lower this morning, with the Dow Jones index falling around 100 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.22% to 44,374.15 while the NASDAQ fell 0.27% to 19,661.13. The S&amp;P 500 also fell, dropping, 0.24% to 6,052.08.
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43623929/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-6">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Materials shares surged by 0.4% on Tuesday.
In trading on Tuesday, utilities shares fell by 0.8%.
Top Headline
Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) posted better-than-expected fourth-quarter earnings results.
The company reported fourth-quarter sales growth of 6% year-on-year to $11.5 billion, beating the analyst consensus estimate of $10.677 billion.
Operating income for the quarter increased 19.2% to $2.7 billion. Adjusted EPS of 55 cents beat the consensus estimate of 52 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Blue Hat Interactive Entertainment Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) shares shot up 90% to $0.1306.</li>
<li>Shares of Ocean Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>)got a boost, surging 48% to $0.2187. Ocean Biomedical recently announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates.</li>
<li>SelectQuote, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLQT#NYSE">SLQT</a>) shares were also up, gaining 47% to $6.42 after the company reported better-than-expected second-quarter financial results and issued FY25 revenue guidance above estimates. Additionally, the company announced a $350 million strategic investment from several institutional investors.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) shares dropped 48% to $6.85 after the company reported worse-than-expected first-quarter financial results and issued FY25 revenue guidance below estimates.</li>
<li>Shares of Columbus McKinnon Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCO#NASDAQ">CMCO</a>) were down 41% to $21.05 following downbeat quarterly results. Columbus McKinnon also announced plans to combine with Kito Crosby.</li>
<li>Hyperfine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) was down, falling 33% to $1.1276 after the company announced a $6 million registered direct offering.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $73.27 while gold traded down 0.3% at $2,926.70.
Silver traded down 0.9% to $32.205 on Tuesday, while copper fell 3% to $4.5645.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.1%, Germany's DAX 40 rose 0.3% and France's CAC 40 rose 0.2%. Spain's IBEX 35 Index rose 0.3%, while London's FTSE 100 fell 0.1%.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with China's Shanghai Composite Index falling 0.12%, Hong Kong's Hang Seng Index dipping 1.06% and India's BSE Sensex falling 1.32%.
Economics
The NFIB Small Business Optimism Index declined to 102.8 in January compared to 105.1 in the previous month, and down from estimates of 104.6.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43622959/how-to-earn-500-a-month-from-exelon-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Exelon Stock Ahead Of Q4 Earnings</a></li>
</ul>

Eurozone

BHAT

CMCO

FLNC

HYPR

OCEA

SLQT

Dow Falls 100 Points; Coca-Cola Posts Upbeat Earnings

AXSM

Axsome Therapeutics shares are trading higher after Mizuho raised its price target on the stock from $137 to $195 and B of A Securities raised its target from $143 to $167.

AIFF

Firefly Neuroscience Shares Resumed Trade

<a href="https://www.youtube.com/watch?v=aavRKJYuJkE" title="https://www.youtube.com/watch?v=aavRKJYuJkE">https://www.youtube.com/watch?v=aavRKJYuJkE</a>

Government

Macro Economic Events

Economics

Federal Reserve

Fed Chair Powell Says Current Rates Make Fed "Well Positioned To Deal With The Risks"

Canaccord Genuity analyst Susan Anderson maintains Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) with a Buy and lowers the price target from $53 to $40.

Canaccord Genuity Maintains Buy on Edgewell Personal Care, Lowers Price Target to $40

ATIIU

Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

HLNE

Hamilton Lane shares are trading lower after the company announced a $252 million public offering of class A common stock.

Firefly Neuroscience Shares Halted On Circuit Breaker To The Upside, Stock Now Up 63.2%

Press Releases

Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024

Grace Therapeutics Announces Second Fiscal Quarter 2025  Financial Results, Provides Business Update

Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

ACST

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

AN2 Therapeutics

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Context Therapeutics

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Impact BioMedical

IGC Pharma

Opus Genetics

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

Marinus Pharmaceuticals, Inc. - Common Stock

Marinus Pharma

NRX Pharmaceuticals

OptiNose

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

SCYNEXIS

Traws Pharma

Verrica Pharmaceuticals Inc. - Common Stock

Comments

Grace Therapeutics

Grace Therapeutics (GRCE) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga